About David Cohne

David Cohne has 20 years of experience as an investment analyst and writer. Prior to StockNews, David spent eleven years as a consultant providing outsourced investment research and content to financial services companies, hedge funds, and online publications. He also served as a Consultant and Senior Investment Writer to NextShares Solutions LLC where he provided content on Exchange-Traded Products.

He is the Chief Value Strategist for StockNews.com and the editor of POWR Value newsletter.

Previously, David was Vice President and Director of Research at The Rankings Service, an independent investment research and consulting firm that scored and ranked mutual fund managers. He also served as Vice President and Senior Analyst at Fundworks Inc, a financial newsletter publishing firm. David started his career in portfolio management at Adviser Investments, an independent wealth management firm. He received an undergraduate degree in Economics at Brandeis University and an MBA from Arizona State University.

David enjoys researching and writing about stocks and the markets. He takes a fundamental quantitative approach in evaluating stocks for readers. If you would like to see more of his best value stock ideas, then click the following link: See David Cohne's Favorite Value Stocks.

Recent Articles By David Cohne

: GSK |  News, Ratings, and Charts

GlaxoSmithKline: My Top Value Stock for the Week

GlaxoSmithKline PLC (GSK) is one of the biggest pharmaceuticals companies in the world. The firm, which has a focus in HIV, vaccines, and cancers, is seeing a lot of success with new drugs and plenty more in the pipeline. Better yet, the stock is still very undervalued, which is why investors should consider adding it to their portfolios.
: AMAT |  News, Ratings, and Charts

Buy These 3 Tech Stocks Before They Soar Further

Tech stocks, which were underperformers at the start of the year, have made their way back as investors have been buying on the dip. Many of these stocks, which include Applied Materials Inc. (AMAT), KLA Corporation (KLAC), and Amdocs Limited (DOX) are currently in an uptrend and are expected to continue this momentum.
: SPY |  News, Ratings, and Charts

What Banks' Q3 Earnings Mean for the Stock Market

While many investors were concerned about a sharp drop in growth after the second quarter's historical earnings season, it seems those concerns may have been premature. Banks started earnings season with better-than-expected results which have calmed any investor concerns. Other companies followed suit and have so far shown similar results. It appears that supply chain challenges, labor shortages, and rising prices have not harmed profits as previously thought, as these companies have been able to navigate these issues. We are now looking at a better environment for the S&P 500 (SPY) with a strong start to the corporate earnings season and positive economic data. I’ll discuss this and more below…
: WGO |  News, Ratings, and Charts

3 Ridiculously Cheap Auto Stocks That Are Screaming Buys

The global chip shortage has greatly affected the production of new automobiles. However, this has been a boon to used-cars, parts, and supplies as prices have jumped. It has also been great for RV stocks as the demand has not been as affected by these issues. That's why investors should consider undervalued automotive stocks such as Winnebago Industries, Inc. (WGO), AutoNation, Inc. (AN), Sonic Automotive, Inc. (SAH) that could see their shares rise in the months ahead.
: OMCL |  News, Ratings, and Charts

3 Mid-Cap Stocks with Large-Cap Potential

Large-cap stocks get all the attention, but investors would be wise to also consider adding mid-cap stocks to their portfolios. Not only do they offer higher growth potential, but they also can help diversify a portfolio. That’s why investors should take a look at highly rated mid-cap growth stocks such as Omnicell, Inc. (OMCL), Alkermes PLC (ALKS), and PVH Corp. (PVH).
: CORT |  News, Ratings, and Charts

Why Corcept Therapeutics is a Great Value Stock to Buy

Biotech stocks have certainly gained prominence over the past year and a half as a result of companies looking for treatments for COVID. The biotech industry is expected to continue growing due to the needs of aging baby boomers. What better way to invest in biotech than investing in a highly undervalued stock such as Corcept Therapeutics (CORT).
: SPY |  News, Ratings, and Charts

How Will Ongoing Price Increases Impact the Stock Market?

Volatility has been the name of the game for the S&P 500 (SPY) the last few weeks as investor optimism over the summer has turned into pessimism recently. A host of concerns have kept investors ruminating, with higher prices being the most pressing. We saw disappointing employment and CPI figures recently, but things aren't as bad as they seem. The economy is on solid footing and continues to grow, which should help support equity prices going forward. I’ll discuss this and more below…
: R |  News, Ratings, and Charts

3 Growth Stocks That Could Be Huge Winners in the Fourth Quarter

The average year-over-year growth estimate for the fourth quarter is expected to be the third largest increase in over ten years. That means investors should consider growth stocks in sectors with the highest growth potential. Three great examples are as Ryder System, Inc. (R), Greif Inc. (GEF), and Westlake Chemical Corporation (WLK).
: RDS.A |  News, Ratings, and Charts

3 Energy Stocks to Buy as Oil Prices Surge

Oil prices continue to surge due to increased demand and low supply. Shares of energy stocks have risen due to these higher prices. With no end in sight, investor should consider Buy-rated energy stocks such as Royal Dutch Shell PLC (RDS.A), TotalEnergies SE ADR (TTE), and BP PLC ADR (BP).
: MKSI |  News, Ratings, and Charts

3 Top Stocks with Upsides Over 50%, According to Wall Street Analysts

Growth stocks have seen their shares fall quite a bit recently due to lofty valuations and the rise in treasury yields. That’s why investors should consider adding value stocks to their portfolio. But instead of relying on traditional valuation measures, investors should consider stocks trading well below their upside potential such as MKS Instruments, Inc. (MKSI), Medifast Inc. (MED), and Amarin Corp. PLC ADR (AMRN).
Page generated in 0.5215 seconds.